The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial
Wissenschaftlicher Artikel
Autoren
Hadji, Peyman
Stoetzer, Oliver
Decker, Thomas
Kurbacher, Christian M.
Marme, Frederik
Institutionen
UKU. Klinik für Frauenheilkunde und GeburtshilfeErschienen in
Journal of Bone Oncology ; 14 (2019). - Art.-Nr. UNSP 100199. - ISSN 2212-1374